CoChat

AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis

Open access
Barbalho, Sandra Maria, Laurindo, Lucas Fornari, de Oliveira Zanuso, Bárbara, da Silva, Rebeca Maria Siqueira, Gallerani Caglioni, Lívia, Nunes Junqueira de Moraes, Victor Bruno Fonseca, Fornari Laurindo, Lívia, Dogani Rodrigues, Victória, da Silva Camarinha Oliveira, Jéssica, Beluce, Maria Eduarda, Penteado Detregiachi, Cláudia Rucco, Barbalho Lamas, Caroline, dos Santos Haber, Jesselina Francisco, Cavallari Strozze Catharin, Virgínia Maria, Quesada, Karina, Tanaka, Masaru, Valenti, Vitor Engrácia · 2025 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, and neuroinflammation. Despite advancements in early detection, diagnosis, and treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, and the limited efficacy of current therapies. Consequently, there is a pressing need for novel therapeutic agents to target the multifaceted aspects of AD pathology, enhance current treatments, and minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest for its potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, and mitigating tau hyperphosphorylation. This review aimed to evaluate the effects of AdipoRon-based adiponectin replacement therapy against AD, using a comprehensive approach grounded in the PICO framework—Population, Intervention, Comparison, and Outcomes. A total of six studies were reviewed, including in vitro and in vivo investigations examining AdipoRon’s impact on various AD models. These studies involved different cell lines and transgenic mouse models, assessing various outcomes such as cognitive function, neuroinflammation, tau phosphorylation, synaptic deficiencies, and relevant molecular pathways. By synthesizing data from these studies, our review thoroughly explains AdipoRon’s neuroprotective effects, mechanisms of action, and potential as a therapeutic agent for AD. This analysis aims to highlight the current state of knowledge, identify gaps in the research, and suggest directions for future studies and clinical applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms26020484

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Molecular Structure of AdipoRon. AdipoRon, with the molecular formula C27H28N2O3, has a molecular weight of 428.5 g/mol. Its exact mass is 428.20999276 Da, aligning with its monoisotopic mass. The compound exhibits high lipophilicity, with an XLogP3-AA value of 4.7, indicating it is more soluble in fats than water. It has one hydrogen bond donor and four hydrogen bond acceptors, suggesting its capacity for hydrogen bonding and potential interactions with other molecules. AdipoRon features eight rotatable bonds, reflecting its structural flexibility. Its topological polar surface area is 58.6 Å2, suggesting moderate polarity, influencing its ability to cross biological membranes. With a heavy atom count of 32, AdipoRon is relatively complex, and its complexity value of 582 further supports this. The compound is electrically neutral with a formal charge of 0 and lacks chiral centers, indicating no stereoisomerism. These properties highlight AdipoRon’s lipophilic nature, structural complexity, and potential behavior in biological contexts [91].
Figure 1 Molecular Structure of AdipoRon. AdipoRon, with the molecular formula C27H28N2O3, has a molecular weight of 428.5 g/mol. Its exact mass is 428.20999276 Da, aligning with its monoisotopic mass. The compound exhibits high lipophilicity, with an XLogP3-AA value of 4.7, indicating it is more soluble in fats than water. It has one hydrogen bond donor and four hydrogen bond acceptors, suggesting its capacity for hydrogen bonding and potential interactions with other molecules. AdipoRon features eight rotatable bonds, reflecting its structural flexibility. Its topological polar surface area is 58.6 Å2, suggesting moderate polarity, influencing its ability to cross biological membranes. With a heavy atom count of 32, AdipoRon is relatively complex, and its complexity value of 582 further supports this. The compound is electrically neutral with a formal charge of 0 and lacks chiral centers, indicating no stereoisomerism. These properties highlight AdipoRon’s lipophilic nature, structural complexity, and potential behavior in biological contexts [91].CC BY · PubMed Central
Figure 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicting the systematic review process. AD, Alzheimer’s disease.
Figure 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicting the systematic review process. AD, Alzheimer’s disease.CC BY · PubMed Central
Figure 3 Meta-analysis for overall effects of AdipoRon on novel object preference [99,102].
Figure 3 Meta-analysis for overall effects of AdipoRon on novel object preference [99,102].CC BY · PubMed Central
Figure 4 Meta-analysis for overall effects of AdipoRon on time spent in the novel arm [100,102].
Figure 4 Meta-analysis for overall effects of AdipoRon on time spent in the novel arm [100,102].CC BY · PubMed Central
Figure 5 Meta-analysis for overall effects of AdipoRon on time spent in the target quadrant [100,101,102].
Figure 5 Meta-analysis for overall effects of AdipoRon on time spent in the target quadrant [100,101,102].CC BY · PubMed Central
Figure 6 Meta-analysis for overall effects of AdipoRon on total arm entries [98,100].
Figure 6 Meta-analysis for overall effects of AdipoRon on total arm entries [98,100].CC BY · PubMed Central
Figure 7 Meta-analysis for overall effects of AdipoRon on escape latency [98,99,100,101].
Figure 7 Meta-analysis for overall effects of AdipoRon on escape latency [98,99,100,101].CC BY · PubMed Central
Figure 8 Meta-analysis for overall effects of AdipoRon on swimming speed [99,100].
Figure 8 Meta-analysis for overall effects of AdipoRon on swimming speed [99,100].CC BY · PubMed Central
Figure 9 Meta-analysis for overall effects of AdipoRon on crossing times [98,99].
Figure 9 Meta-analysis for overall effects of AdipoRon on crossing times [98,99].CC BY · PubMed Central
Figure 10 Adiponectin synthesis and effects of AdipoRon against Alzheimer’s Disease. Adiponectin from adipose tissue presents several neuroprotective mechanisms that influence the activity of Adiponectin Receptor 1 (AdipoR1) and Adiponectin Receptor 2 (AdipoR2) receptors in the central nervous system. Since AdipoRon is an adiponectin receptor agonist, this molecule is expected to show the same neuroprotective effects. The evidence suggests that while modulating AdipoR1 and AdipoR2, AdipoRon affects Adenosine Monophosphate-Activated Protein Kinase (AMPK), Peroxisome Proliferator-Activated Receptor (PPAR), Mammalian Target of Rapamycin (mTOR), Sirtuin (SIRT), and Glycogen Synthase Kinase 3 Beta (GSK3β) signaling pathways. By acting on these signaling pathways, AdipoRon can exert many beneficial effects against Alzheimer’s disease, improving Amyloid-Beta (Aβ) deposition and clearance, enhancing cognitive function and brain insulin resistance, and activating autophagy.
Figure 10 Adiponectin synthesis and effects of AdipoRon against Alzheimer’s Disease. Adiponectin from adipose tissue presents several neuroprotective mechanisms that influence the activity of Adiponectin Receptor 1 (AdipoR1) and Adiponectin Receptor 2 (AdipoR2) receptors in the central nervous system. Since AdipoRon is an adiponectin receptor agonist, this molecule is expected to show the same neuroprotective effects. The evidence suggests that while modulating AdipoR1 and AdipoR2, AdipoRon affects Adenosine Monophosphate-Activated Protein Kinase (AMPK), Peroxisome Proliferator-Activated Receptor (PPAR), Mammalian Target of Rapamycin (mTOR), Sirtuin (SIRT), and Glycogen Synthase Kinase 3 Beta (GSK3β) signaling pathways. By acting on these signaling pathways, AdipoRon can exert many beneficial effects against Alzheimer’s disease, improving Amyloid-Beta (Aβ) deposition and clearance, enhancing cognitive function and brain insulin resistance, and activating autophagy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. (2024, July 22). National Library of Medicine, National Library of Medicine-National Institute of Health. AdipoRon, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/AdipoRon.

Cited by

See all 22

Metadata

Authors
Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., Penteado Detregiachi, C. R., Barbalho Lamas, C., dos Santos Haber, J. F., Cavallari Strozze Catharin, V. M., Quesada, K., Tanaka, M., & Valenti, V. E.
Affiliations
  • São Paulo State Technological College (BR)
  • Faculdade de Medicina de São José do Rio Preto (BR)
  • Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, São Paulo, Brazil
  • Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília (FAMEMA), Marília 17519-030, São Paulo, Brazil
  • Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto 15090-000, São Paulo, Brazil
  • Universidade de Marília (BR)
  • Department of Gerontology, School of Gerontology, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, São Paulo, Brazil
  • University of Szeged (HU)
  • Autonomic Nervous System Center, School of Philosophy and Sciences, São Paulo State University, Marília 17525-902, São Paulo, Brazil
Corresponding author
Tanaka, Masaru
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-01-08
Volume
26
Issue
2
Pages
484
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4406170873
Cited by
18
References
148
Citations by year
2026: 6 · 2025: 12
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
HUN-REN Hungarian Research Network
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
AdipoRon, adiponectin receptor agonist, Alzheimer's disease, neuroprotection, neuroinflammation, tau hyperphosphorylation, synaptic dysfunction, mitochondrial function, cognitive function, transgenic mouse model, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Humans, Indenes, Piperidines, tau Proteins, Neuroprotective Agents, Adiponectin, Receptors, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.